Exelixis
EXEL
#1680
Rank
C$14.21 B
Marketcap
$49.78
Share price
2.24%
Change (1 day)
67.67%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.38

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.40. In 2022 the company made an earnings per share (EPS) of $0.80 a decrease over its 2021 EPS that were of $1.03.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.38-52.83%
2022$0.80-22.97%
2021$1.03100%
2020$0.52-65.09%
2019$1.48-53.91%
2018$3.22333.96%
2017$0.74-260.61%
2016-$0.46-58.75%
2015-$1.12-42.45%
2014-$1.945.3%
2013-$1.8543.48%
2012-$1.29-264.29%
2011$0.78-165.88%
2010-$1.19-32.54%
2009-$1.76-17.65%
2008-$2.1475.86%
2007-$1.22-25.64%
2006-$1.648.33%
2005-$1.51-42.86%
2004-$2.6430.34%
2003-$2.03-5.23%
2002-$2.14-0.65%
2001-$2.15-51.88%
2000-$4.47

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$4.89 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.45 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.55 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.55 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$19.78 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$19.69 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.60 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.98-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.17-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA